Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
134 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2017 Summary Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 38 molecules. Out of which approximately 37 molecules are developed by companies and remaining by the universities/institutes. The latest report Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2017, outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory co-receptor CD28. Inhibition of receptor acts as a major negative regulator of T-cell responses. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 3, 4, 18, 8 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Gastric Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Breast Cancer, Hepatocellular Carcinoma, Melanoma, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Non-Hodgkin Lymphoma, Small-Cell Lung Cancer, Adenoid Cystic Carcinoma (ACC), Anaplastic Thyroid Cancer, Bladder Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Papillary Renal Cell Carcinoma, Peritoneal Cancer, Primitive Neuroectodermal Tumor (PNET), Renal Cell Carcinoma, Adrenal Gland Cancer, Advanced Malignancy, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Dysgerminoma, Ependymoma, Esophageal Cancer, Ewing Sarcoma, Gastroesophageal (GE) Junction Carcinomas, Germ Cell Tumors, Germinomatous (Seminomatous) Germ Cell Tumors, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kaposi Sarcoma, Lymphoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Medulloblastoma, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Salivary Gland Cancer, Skin Cancer, Soft Tissue Sarcoma, Ureter Cancer, Urethral Cancer and Urinary Tract Cancer. Furthermore, this report also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects - The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Overview 10 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Development 11 Products under Development by Stage of Development 11 Products under Development by Therapy Area 12 Products under Development by Indication 13 Products under Development by Companies 17 Products under Development by Universities/Institutes 29 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Assessment 31 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Companies Involved in Therapeutics Development 37 Aduro BioTech Inc 37 Agenus Inc 38 Alligator Bioscience AB 39 Bristol-Myers Squibb Company 40 Cold Genesys Inc 43 Crown Bioscience Inc 43 Five Prime Therapeutics Inc 44 Globavir Biosciences Inc 44 Humorigin Biotechnology Corp 45 Immunocore Ltd 45 Immunwork Inc 46 Innovent Biologics Inc 46 JHL Biotech Inc 47 MacroGenics Inc 48 MedImmune LLC 49 Merck & Co Inc 51 OncoImmune Inc 51 Premier Biomedical Inc 52 Serometrix LLC 52 Sutro Biopharma Inc 53 Tikcro Technologies Ltd 53 Xencor Inc 54 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Drug Profiles 55 10B-10 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 AGEN-1884 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 AGEN-2041 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Antisense Oligonucleotide to Inhibit CTLA4 for Melanoma - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 ATOR-1015 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Biologic to Antagonize CTLA4 for Solid Tumor - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Bispecific Monoclonal Antibodies to Antagonize PD-1 and CTLA-4 for Solid Tumor and Hematological Tumor - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Bispecific Monoclonal Antibody to Antagonize CTLA-4 for Oncology - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Bispecific Monoclonal Antibody to Target CTLA-4 and LAG-3 for Oncology - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 CG-0070 + Immune Checkpoint Modulator - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 CG-0161 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 CNC-225 + CNC-118 + Anti-CTLA-4 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 durvalumab + IMCgp-100 + tremelimumab - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 durvalumab + tremelimumab - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 FPT-155 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 HOR-010 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 IBI-310 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 ipilimumab - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 ipilimumab + nivolumab - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 JMW-3B3 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 KN-044 - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 MEDI-0562 + tremelimumab - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 MEDI-3617 + tremelimumab - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 MK-1308 - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 Monoclonal Antibodies to Antagonize 1 PD-1 and CTLA-4 for Solid Tumor and Hematological Tumor - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 Monoclonal Antibodies to Antagonize CTLA-4 for Metastatic Melanoma - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile 106 Product Description 106 Mechanism Of Action 106 R&D Progress 106 Monoclonal Antibody to Inhibit CTLA-4 for Oncology - Drug Profile 107 Product Description 107 Mechanism Of Action 107 R&D Progress 107 Monoclonal Antibody to Inhibit CTLA4 for Breast Cancer - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 ONC-392 - Drug Profile 109 Product Description 109 Mechanism Of Action 109 R&D Progress 109 Small Molecule to Antagonize CTLA-4 for Oncology - Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 Small Molecules to Inhibit CTLA4 for Oncology - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 SNCA-21 - Drug Profile 112 Product Description 112 Mechanism Of Action 112 R&D Progress 112 TE-1254 - Drug Profile 113 Product Description 113 Mechanism Of Action 113 R&D Progress 113 tremelimumab - Drug Profile 114 Product Description 114 Mechanism Of Action 114 R&D Progress 114 XmAb-20717 - Drug Profile 118 Product Description 118 Mechanism Of Action 118 R&D Progress 118 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Dormant Products 119 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Discontinued Products 121 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Product Development Milestones 122 Featured News & Press Releases 122 Aug 15, 2017: Bristol-Myers Squibb Announces Topline Results from CheckMate -214, a Phase 3 Study of Opdivo in Combination with Yervoy in Intermediate and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma 122 Jul 27, 2017: AstraZeneca reports initial results from the ongoing MYSTIC trial in Stage IV lung cancer 122 Jul 26, 2017: NICE approval for nivolumab provides new treatment for advanced blood cancer 123 Jul 24, 2017: U.S. Food and Drug Administration Expands Approval of Yervoy (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma 123 Jul 08, 2017: Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015 125 Jul 05, 2017: Combo immunotherapy may herald new standard of care for kidney cancer 125 Jun 05, 2017: Agenus anti-CTLA-4 antibody shows strong safety and tolerability 126 Jun 04, 2017: New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in Resected High-Risk Melanoma Patients Presented at ASCO 126 Jun 04, 2017: Combination therapy shown to shrink tumours in many advanced melanoma patients whose cancer has spread to the brain 127 Jun 04, 2017: First Presentation of Efficacy Data from CheckMate-204 Evaluating the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Demonstrates Anti-tumor Activity in Advanced Melanoma Patients with Brain Metastases 128 Jun 03, 2017: Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrated Promising Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer in Phase 2 CheckMate -142 Study 129 May 22, 2017: Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting 130 May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ATOR-1015 131 Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4 131 Apr 04, 2017: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibbs Application for Opdivo in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer 131 Appendix 133 Methodology 133 Coverage 133 Secondary Research 133 Primary Research 133 Expert Panel Validation 133 Contact Us 133 Disclaimer 134
List of Tables
Number of Products under Development by Stage of Development, H2 2017 11 Number of Products under Development by Therapy Areas, H2 2017 12 Number of Products under Development by Indications, H2 2017 13 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15 Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 16 Number of Products under Development by Companies, H2 2017 17 Number of Products under Development by Companies, H2 2017 (Contd..1) 18 Products under Development by Companies, H2 2017 19 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 20 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 21 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 22 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 23 Products under Development by Companies, H2 2017 (Contd..5), H2 2017 24 Products under Development by Companies, H2 2017 (Contd..6), H2 2017 25 Products under Development by Companies, H2 2017 (Contd..7), H2 2017 26 Products under Development by Companies, H2 2017 (Contd..8), H2 2017 27 Products under Development by Companies, H2 2017 (Contd..9), H2 2017 28 Number of Products under Investigation by Universities/Institutes, H2 2017 29 Products under Investigation by Universities/Institutes, H2 2017 30 Number of Products by Stage and Mechanism of Actions, H2 2017 32 Number of Products by Stage and Route of Administration, H2 2017 34 Number of Products by Stage and Molecule Type, H2 2017 36 Pipeline by Aduro BioTech Inc, H2 2017 37 Pipeline by Agenus Inc, H2 2017 38 Pipeline by Alligator Bioscience AB, H2 2017 39 Pipeline by Bristol-Myers Squibb Company, H2 2017 40 Pipeline by Cold Genesys Inc, H2 2017 43 Pipeline by Crown Bioscience Inc, H2 2017 43 Pipeline by Five Prime Therapeutics Inc, H2 2017 44 Pipeline by Globavir Biosciences Inc, H2 2017 44 Pipeline by Humorigin Biotechnology Corp, H2 2017 45 Pipeline by Immunocore Ltd, H2 2017 45 Pipeline by Immunwork Inc, H2 2017 46 Pipeline by Innovent Biologics Inc, H2 2017 46 Pipeline by JHL Biotech Inc, H2 2017 47 Pipeline by MacroGenics Inc, H2 2017 48 Pipeline by MedImmune LLC, H2 2017 49 Pipeline by Merck & Co Inc, H2 2017 51 Pipeline by OncoImmune Inc, H2 2017 51 Pipeline by Premier Biomedical Inc, H2 2017 52 Pipeline by Serometrix LLC, H2 2017 52 Pipeline by Sutro Biopharma Inc, H2 2017 53 Pipeline by Tikcro Technologies Ltd, H2 2017 53 Pipeline by Xencor Inc, H2 2017 54 Dormant Products, H2 2017 119 Dormant Products, H2 2017 (Contd..1), H2 2017 120 Discontinued Products, H2 2017 121
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
